Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

Rhea-AI Summary

Nascent Biotech (OTCQB:NBIO) has announced positive initial In-Vitro study results in collaboration with Syracuse University, demonstrating that Pritumumab (PTB) effectively blocks viral entry of SARS-CoV-2. This antibody, known for its cancer-fighting properties, shows potential for further development in tackling COVID-19. Senior Medical Consultant Dr. Navpaul Singh emphasized that less viral load correlates with reduced patient symptoms, suggesting PTB could be used in combination therapies. The company is also advancing its Phase I Brain Cancer Clinical Trial.

Positive

• Initial In-Vitro study results indicate Pritumumab (PTB) effectively blocks SARS-CoV-2 entry into cells.
• Potential for PTB to be developed as a treatment for COVID-19.
• Management continues development in viral infections and is opening a Phase I Brain Cancer Clinical Trial.

Negative

• None.

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB") successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies.

Alison Patteson, an assistant professor of physics, is leading a team researching the connections between the COVID-19 virus and pritumumab, a naturally occurring antibody, which has been used to inhibit cancer and tumor growth. Patteson tested whether the antibody blocks SARS-CoV-2, the virus responsible for COVID-19, from entering cells. "Evidence has been found that the antibody does block the uptake to viral particles," Patteson said. The entire Syracuse Press release can be seen at: http://dailyorange.com/2020/10/professor-researches-antibody-possible-treatment-covid-19/

Nascent Senior Medical Consultant, Dr. Navpaul Singh M.D., stated, "the In Vitro results indicating that PTB can block uptake of COVID-19 is great as less viral load corresponds to less patient symptoms. These results may be suggestive of use in a combination therapy with drugs targeting other pathways. "

An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent's investigation into Viral Infections.

Nascent's Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.

About Nascent Biotech Inc

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Sean Carrick
CEO Nascent Biotech, Inc
6330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
(612) 961-5656
Sean.carrick@nascentbiotech.com

SOURCE: Nascent Biotech, Inc.

View source version on accesswire.com:
https://www.accesswire.com/611039/Nascent-Biotech-Announces-Promising-Covid-19-Invitro-Study-Results-with-Syracuse-University-Collaboration

FAQ

What are the initial study results of Pritumumab (PTB) from Nascent Biotech?

The initial In-Vitro study results show that Pritumumab effectively blocks SARS-CoV-2 from entering cells.

When is the Phase I Brain Cancer Clinical Trial starting for Nascent Biotech?

Nascent Biotech is opening the Phase I Brain Cancer Clinical Trial, though specific dates were not provided in the press release.

What collaboration did Nascent Biotech engage in for COVID-19 research?

Nascent Biotech collaborated with Syracuse University to study the effects of Pritumumab on blocking COVID-19 viral entry.

What potential does Pritumumab have in relation to COVID-19 according to Nascent Biotech?

Pritumumab may be used in combination therapies targeting other pathways to reduce patient symptoms related to COVID-19.